Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.

The benefit of cytoreductive surgery for glioblastoma multiforme (GBM) is unclear, and selection bias in past series has been observed. The 5-aminolevulinic acid (ALA) study investigated the influence of fluorescence-guided resections on outcome and generated an extensive database of GBM patients with optimized resections. We evaluated whether the Radiation Therapy Oncology Group recursive partitioning analysis (RTOG-RPA) would predict survival of these patients and whether there was any benefit from extensive resections depending on RPA class. A total of 243 per-protocol patients with newly diagnosed GBM were operated on with or without ALA and treated by radiotherapy. Postoperative MRI was obtained in all patients. Patients were allocated into RTOG-RPA classes III-V based on age, KPS, neurological condition, and mental status (as derived from the NIH Stroke Scale). Median overall survival among RPA classes III, IV, and V was 17.8, 14.7, and 10.7 months, respectively, with 2-year survival rates of 26%, 12%, and 7% (p = 0.0007). Stratified for degree of resection, survival of patients with complete resections was clearly longer in RPA classes IV and V (17.7 months vs. 12.9 months, p = 0.0015, and 13.7 months vs. 10.4 months, p = 0.0398; 2-year rates: 21.0% vs. 4.4% and 11.1% vs. 2.6%, respectively), but was not in the small subgroup of RPA class III patients (19.3 vs. 16.3 months, p = 0.14). Survival of patients from the ALA study is correctly predicted by the RTOG-RPA classes. Differences in survival depending on resection status, especially in RPA classes IV and V, support a causal influence of resection on survival.

[1]  M. Prados,et al.  Radiation response and survival time in patients with glioblastoma multiforme. , 1996, Journal of neurosurgery.

[2]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[3]  C. Avezaat,et al.  The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[4]  M. Pessin,et al.  Serial Assessment of Acute Stroke Using the NIH Stroke Scale , 1994, Stroke.

[5]  Klaus Sartor,et al.  Early Postoperative Magnetic Resonance Imaging after Resection of Malignant Glioma: Objective Evaluation of Residual Tumor and Its Influence on Regrowth and Prognosis , 1995 .

[6]  W. Curran,et al.  Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. , 2000, International journal of radiation oncology, biology, physics.

[7]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Piérart,et al.  Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Curran,et al.  Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Takakura,et al.  Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. , 1997, Neurosurgery.

[11]  L. Zamorano,et al.  Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. , 1999, International journal of radiation oncology, biology, physics.

[12]  James N. Davis,et al.  Interrater reliability of the NIH stroke scale. , 1989, Archives of neurology.

[13]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[14]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[15]  L. Zamorano,et al.  Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis. , 2001, International journal of radiation oncology, biology, physics.

[16]  K. Sultanem,et al.  The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. , 2004, International journal of radiation oncology, biology, physics.

[17]  Susan M. Chang,et al.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. , 2004, Neuro-oncology.

[18]  W. Curran,et al.  Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.

[19]  O. Witte,et al.  Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. , 1997, Neurosurgery.

[20]  D. Nelson,et al.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.

[21]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[22]  J. Jääskeläinen,et al.  Debulking or biopsy of malignant glioma in elderly people – a randomised study , 2003, Acta Neurochirurgica.

[23]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Fisher,et al.  Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. , 2002, International journal of radiation oncology, biology, physics.

[25]  H. Adams,et al.  Ensuring Reliability of Outcome Measures in Multicenter Clinical Trials of Treatments for Acute Ischemic Stroke: The Program Developed for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) , 1994, Stroke.

[26]  Veit Rohde,et al.  EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.

[27]  W. Curran,et al.  Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.